- Previous Close
32.61 - Open
32.58 - Bid 32.50 x 100
- Ask 33.09 x 100
- Day's Range
32.20 - 33.60 - 52 Week Range
27.69 - 76.14 - Volume
185,266 - Avg. Volume
277,272 - Market Cap (intraday)
1.645B - Beta (5Y Monthly) 0.72
- PE Ratio (TTM)
-- - EPS (TTM)
-0.95 - Earnings Date Feb 26, 2025 - Mar 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
62.81
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
www.immunocore.comRecent News: IMCR
View MorePerformance Overview: IMCR
Trailing total returns as of 2/1/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IMCR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IMCR
View MoreValuation Measures
Market Cap
1.65B
Enterprise Value
1.22B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.53
Price/Book (mrq)
4.35
Enterprise Value/Revenue
4.13
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-15.88%
Return on Assets (ttm)
-5.22%
Return on Equity (ttm)
-12.83%
Revenue (ttm)
296.31M
Net Income Avi to Common (ttm)
-47.05M
Diluted EPS (ttm)
-0.95
Balance Sheet and Cash Flow
Total Cash (mrq)
901.28M
Total Debt/Equity (mrq)
127.32%
Levered Free Cash Flow (ttm)
42.44M